FDA approves Lilly’s Mounjaro to reduce cardiovascular risk in type 2 diabetes patients The U. S. Food and Drug Administration has approved Eli Lilly’s Mounjaro to minimise the risk of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular. ..



